Syros Pharmaceuticals, Inc. (SYRS)
Largest Insider Buys in Sector
SYRS Stock Price History Chart
SYRS Stock Performance
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Syros Pharmaceuticals, Inc.
Over the last 12 months, insiders at Syros Pharmaceuticals, Inc. have bought $4M and sold $139,870 worth of Syros Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Syros Pharmaceuticals, Inc. have bought $1.43M and sold $2.58M worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS (director) — $8M.
The last purchase of 904,977 shares for transaction amount of $4M was made by AKKARAJU SRINIVAS (director) on 2023‑12‑21.
List of Insider Buy and Sell Transactions, Syros Pharmaceuticals, Inc.
| 2024-04-03 | Sale | Roth David | Chief Medical Officer | 10,451 0.0393% | $4.95 | $51,732 | +5.42% | |
| 2024-04-02 | Sale | Roth David | Chief Medical Officer | 150 0.0006% | $4.98 | $747 | +12.61% | |
| 2023-12-21 | AKKARAJU SRINIVAS | director | 904,977 3.271% | $4.42 | $4M | +3.53% | ||
| 2023-12-12 | Sale | Roth David | Chief Medical Officer | 6,287 0.0339% | $4.95 | $31,121 | +22.18% | |
| 2023-12-06 | Sale | Roth David | Chief Medical Officer | 6,287 0.0291% | $3.95 | $24,834 | +45.25% | |
| 2023-07-31 | Sale | Roth David | Chief Medical Officer | 7,348 0.03% | $3.95 | $29,025 | +26.63% | |
| 2023-07-17 | Sale | Olson Eric R | Chief Scientific Officer | 689 0.0025% | $3.50 | $2,412 | +42.19% | |
| 2022-09-29 | TYSON TIMOTHY | 16,932 0.1927% | $6.26 | $105,955 | -34.93% | |||
| 2022-01-05 | Sale | Olson Eric R | Chief Scientific Officer | 4,416 0.0068% | $3.47 | $15,310 | -75.30% | |
| 2021-07-01 | Sale | Olson Eric R | Chief Scientific Officer | 2,328 0.0036% | $5.55 | $12,920 | -38.69% | |
| 2021-03-15 | Sale | Olson Eric R | Chief Scientific Officer | 7,256 0.0119% | $9.47 | $68,743 | -51.33% | |
| 2021-02-16 | Sale | Young Richard A | director | 3,750 0.0061% | $12.05 | $45,188 | -60.05% | |
| 2021-02-08 | Sale | Young Richard A | director | 7,500 0.0125% | $13.04 | $97,800 | -61.50% | |
| 2020-11-17 | Sale | Young Richard A | director | 10,714 0.0183% | $8.75 | $93,748 | -31.57% | |
| 2020-11-16 | Sale | Young Richard A | director | 1,266 0.0022% | $8.98 | $11,369 | -32.73% | |
| 2020-10-19 | Sale | Young Richard A | director | 11,346 0.0192% | $8.75 | $99,278 | -24.47% | |
| 2020-10-15 | Sale | Young Richard A | director | 634 0.0011% | $8.75 | $5,548 | -21.63% | |
| 2020-09-15 | Sale | Young Richard A | director | 11,980 0.0261% | $10.39 | $124,472 | -28.27% | |
| 2020-08-18 | Sale | AKKARAJU SRINIVAS | director | 317,166 0.6574% | $13.10 | $4.15M | -41.09% | |
| 2020-08-18 | Sale | Olson Eric R | Chief Scientific Officer | 21,574 0.0444% | $13.00 | $280,462 | -41.09% |
Insider Historical Profitability
| AKKARAJU SRINIVAS | director | 1786427 6.8691% | $5.70 | 6 | 6 | +15.7% |
| Olson Eric R | Chief Scientific Officer | 6661 0.0256% | $5.70 | 0 | 10 | |
| Roth David | Chief Medical Officer | 0 0% | $5.70 | 0 | 5 | |
| NELSEN ROBERT | 4637137 17.8305% | $5.70 | 1 | 0 | <0.0001% | |
| ARCH Venture Fund VII, L.P. | 10 percent owner | 4242051 16.3114% | $5.70 | 1 | 9 | <0.0001% |
| Flagship Ventures Fund IV, L.P. | 10 percent owner | 3674660 14.1297% | $5.70 | 1 | 0 | <0.0001% |
| Nashat Amir | 1538333 5.9151% | $5.70 | 1 | 0 | <0.0001% | |
| Polaris Management Co. VII, L.L.C. | 10 percent owner | 1538333 5.9151% | $5.70 | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 1466654 5.6395% | $5.70 | 1 | 0 | <0.0001% |
| AISLING CAPITAL III LP | 10 percent owner | 908565 3.4936% | $5.70 | 1 | 0 | <0.0001% |
| Redmile Group, LLC | 10 percent owner | 366739 1.4102% | $5.70 | 1 | 0 | <0.0001% |
| Young Richard A | director | 321711 1.237% | $5.70 | 0 | 16 | |
| Springhorn Jeremy P. | Chief Business Officer | 35000 0.1346% | $5.70 | 3 | 0 | +53.59% |
| TYSON TIMOTHY | 24932 0.0959% | $5.70 | 1 | 0 | <0.0001% | |
| Alles Mark J | director | 10000 0.0385% | $5.70 | 1 | 0 | +13.59% |
| DeSimone Colleen Elizabeth | Principal Accounting Officer | 0 0% | $5.70 | 0 | 1 |
Institutional Investor Ownership
| Bain Capital Life Sciences Investors Llc | $14.71M | 10.29 | 2.75M | 0% | +$0 | 1.48 | |
| Artal Group S A | $13.4M | 9.37 | 2.51M | 0% | +$0 | 0.07 | |
| Adage Capital Partners Gp L L C | $11.08M | 7.75 | 2.07M | 0% | +$0 | 0.02 | |
| Samsara Biocapital Llc | $9.56M | 6.68 | 1.79M | 0% | +$0 | 1.49 | |
| Avidity Partners Management Lp | $8.95M | 6.26 | 1.67M | 0% | +$0 | 0.33 | |
| Point72 Asset Management | $7.87M | 5.51 | 1.47M | 0% | +$0 | 0.02 | |
| Flagship Pioneering | $6.92M | 4.84 | 1.29M | 0% | +$5.35 | 0.45 | |
| The Vanguard Group | $4.97M | 3.47 | 928,046 | +21.34% | +$873,301.88 | <0.0001 | |
| Deep Track Capital Lp | $4.43M | 3.1 | 828,485 | 0% | +$0 | 0.02 | |
| Opaleye Management Inc | $4.21M | 2.95 | 787,545 | +119.15% | +$2.29M | 0.67 | |
| Goldman Sachs | $2.39M | 1.67 | 446,591 | +86.33% | +$1.11M | <0.0001 | |
| Kennedy Capital Management Inc | $2.17M | 1.52 | 404,914 | New | +$2.17M | 0.05 | |
| Blue Owl Capital Holdings Lp | $1.82M | 1.28 | 340,855 | -77.17% | -$6.17M | 0.34 | |
| Walleye Capital | $1.52M | 1.07 | 284,936 | New | +$1.52M | <0.01 | |
| Millennium Management LLC | $1.4M | 0.98 | 261,083 | New | +$1.4M | <0.01 | |
| BlackRock | $1.38M | 0.96 | 257,041 | +4.09% | +$54,018.98 | <0.0001 | |
| Omega Fund Management Llc | $1.34M | 0.94 | 251,270 | 0% | +$0 | 1 | |
| Geode Capital Management | $1.18M | 0.82 | 220,245 | +36.32% | +$314,010.85 | <0.0001 | |
| Ubs Oconnor Llc | $936,250.00 | 0.66 | 175,000 | +34.62% | +$240,750.00 | 0.08 | |
| Jane Street Capital | $922,966.00 | 0.65 | 172,517 | +716.26% | +$809,893.74 | <0.01 | |
| Assenagon Asset Management S.A. | $909,495.00 | 0.64 | 169,999 | +576.48% | +$775,049.45 | <0.01 | |
| Marshall Wace | $853,775.00 | 0.6 | 159,584 | +543.02% | +$720,998.61 | <0.01 | |
| ExodusPoint Capital Management, LP | $829,000.00 | 0.58 | 154,989 | +49.72% | +$275,284.97 | 0.01 | |
| Qube Research & Technologies | $737,663.00 | 0.52 | 137,881 | New | +$737,663.00 | <0.01 | |
| DAFNA Capital Management, LLC | $726,798.00 | 0.51 | 135,850 | -36.78% | -$422,837.54 | 0.17 | |
| Renaissance Technologies | $641,000.00 | 0.45 | 119,835 | +104.38% | +$327,360.12 | <0.01 | |
| Perceptive Advisors | $624,634.00 | 0.44 | 116,754 | New | +$624,634.00 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $407,269.00 | 0.29 | 76,125 | -6.62% | -$28,890.02 | <0.0001 | |
| Two Sigma | $365,314.00 | 0.26 | 68,283 | +24.94% | +$72,915.14 | <0.01 | |
| State Street | $312,601.00 | 0.22 | 58,430 | +18.21% | +$48,150.08 | <0.0001 | |
| LGT Capital Partners | $294,250.00 | 0.21 | 55,000 | 0% | +$0 | 0.01 | |
| Bridgeway Capital Management | $275,525.00 | 0.19 | 51,500 | +30.38% | +$64,200.00 | 0.01 | |
| Man Group Plc | $242,323.00 | 0.17 | 45,294 | New | +$242,323.00 | <0.01 | |
| Northern Trust | $197,399.00 | 0.14 | 36,897 | -7.69% | -$16,440.55 | <0.0001 | |
| Citigroup | $179,888.00 | 0.13 | 33,624 | New | +$179,888.00 | <0.0001 | |
| Bank of America | $180,520.00 | 0.13 | 33,742 | +236.71% | +$126,907.56 | <0.0001 | |
| Balyasny Asset Management Llc | $123,617.00 | 0.09 | 23,106 | New | +$123,617.00 | <0.0001 | |
| T. Rowe Price | $121,000.00 | 0.08 | 22,550 | 0% | +$0 | <0.0001 | |
| 1492 Capital Management, LLC | $116,330.00 | 0.08 | 21,744 | 0% | +$0 | 0.07 | |
| Hrt Financial Llc | $104,000.00 | 0.07 | 19,591 | New | +$104,000.00 | <0.01 | |
| Clarius Group Llc | $99,617.00 | 0.07 | 18,620 | 0% | +$0 | 0.01 | |
| Y Intercept Hong Kong Ltd | $98,777.00 | 0.07 | 18,463 | +75.64% | +$42,537.83 | 0.01 | |
| Morgan Stanley | $93,415.00 | 0.07 | 17,461 | +978.5% | +$84,753.48 | <0.0001 | |
| Acadian Asset Management | $91,000.00 | 0.06 | 17,162 | New | +$91,000.00 | <0.0001 | |
| Brevan Howard Capital Management Lp | $85,793.00 | 0.06 | 16,036 | New | +$85,793.00 | 0.01 | |
| Cibc Asset Management Inc | $82,379.00 | 0.06 | 15,398 | 0% | +$0 | <0.0001 | |
| Hightower Advisors | $80,000.00 | 0.06 | 14,917 | -0.58% | -$466.58 | <0.0001 | |
| Squarepoint Ops LLC | $79,662.00 | 0.06 | 14,890 | New | +$79,662.00 | <0.0001 | |
| American Century Investments | $72,888.00 | 0.05 | 13,624 | New | +$72,888.00 | <0.0001 | |
| Virtu Financial Llc | $64,000.00 | 0.05 | 12,030 | New | +$64,000.00 | 0.01 |